Edition:
United States

Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

30.90EUR
9 Dec 2016
Change (% chg)

€-1.32 (-4.10%)
Prev Close
€32.22
Open
€32.49
Day's High
€32.49
Day's Low
€30.12
Volume
8,493
Avg. Vol
4,062
52-wk High
€45.00
52-wk Low
€24.00

Select another date:

Thu, Dec 1 2016

Carmat shares slump after France halts heart implants

PARIS Shares in artificial heart maker Carmat slumped on Thursday after France's national drugs agency ordered it to suspend further implants following the death of a patient in October.

French drugs agency suspends new Carmat artificial heart implants

PARIS France's national drugs agency said on Wednesday it had ordered artificial heart maker Carmat to suspend further implants after a fifth patient died in October.

BRIEF-Carmat H1 net loss widens to EUR 10.2 mln

* H1 total operating income 96,827 euros ($108,901) vs 2,854 euros year ago

BRIEF-Carmat announces departure of CEO Marcello Conviti

* Carmat announces the departure of CEO Marcello Conviti Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Stéphane Piat has been appointed CEO of Carmat

* Stéphane Piat, previously division vice president of Abbott in California, has been appointed CEO of Carmat

Carmat jumps after first implantation of its bioprosthetic artificial heart

PARIS Carmat's shares jumped on Tuesday after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.

Carmat jumps after first implantation of its bioprosthetic artificial heart

PARIS, Aug 30 Carmat's shares jumped on Tuesday after the French company announced the first implantation of its bioprosthetic artificial heart in a final-stage clinical trial.

BRIEF-Carmat announces start of pivotal study

* Announces that the first implantation of its bioprosthetic artificial heart within the framework of the pivotal study has been carried out in accordance with the authorizations obtained from the ANSM (French national agency for the safety of medicines and health products) and CPP (patient protection committee)

BRIEF-Carmat obtains necessary approvals to begin PIVOTAL study in France

* Carmat has obtained the necessary approvals to begin the PIVOTAL study in France

BRIEF-Carmat begins CE Certification process for its artificial heart

* Carmat has begun, with Dekra, the ce certification process for its bioprosthetic artificial heart

Select another date: